News >

FDA Approval Sought for Erdafitinib in Urothelial Carcinoma

Jason Harris
Published: Wednesday, Sep 19, 2018

Peter F. Lebowitz, MD, PhD

Peter F. Lebowitz, MD, PhD
A new drug application (NDA) has been submitted to the FDA for erdafitinib for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy, according to Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor (TKI).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication